TransMedics to Present at Upcoming March Investor Conferences
Rhea-AI Summary
TransMedics (Nasdaq: TMDX) management will present at two investor conferences in March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:50 p.m. EST, and a virtual presentation at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16, 2026 at 10:00 a.m. EST.
A live and archived webcast and the company's standard investor presentation will be available on the Investors section of the TransMedics website.
Positive
- None.
Negative
- None.
News Market Reaction – TMDX
In the Feb 18 session, TMDX gained 1.26%, reflecting a mild positive market reaction. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings timing | Neutral | -4.3% | Announcement of date and time for Q4 and full-year 2025 results. |
| Feb 09 | Regulatory approval | Positive | +0.9% | Full and unconditional FDA IDE approval for ENHANCE Heart trial. |
| Jan 12 | HQ expansion | Positive | -1.8% | New global headquarters lease and campus expansion in Somerville. |
| Dec 30 | Conference appearance | Neutral | -0.2% | Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 24 | Equity grants | Neutral | -2.2% | Inducement stock options and RSUs granted to five new employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent stock reactions to operational and corporate updates have been mixed, with positive regulatory news aligning with gains while expansion news drew a negative reaction.
Over the last few months, TransMedics announced multiple corporate and regulatory milestones. On Feb 9, 2026, it received full FDA IDE approval for the ENHANCE Heart trial, and the stock rose 0.95%. A January announcement on a new Somerville headquarters and campus drew a -1.76% reaction, suggesting some sensitivity to long-term investment news. Earlier, a J.P. Morgan conference appearance and inducement equity grants in Dec 2025 saw small negative moves. The current investor-conference notice is similar in type to prior event-participation updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Event: TD Cowen 46th Annual Health Care Conference
Date: Monday, March 2, 2026
Time: 1:50 p.m. EST
Event: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Date: Monday, March 16, 2026
Time: 10:00 a.m. EST
A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in
Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-upcoming-march-investor-conferences-302689917.html
SOURCE TransMedics Group, Inc.